PA8720701A1 - Metodos para modular la funciòn de la vejiga - Google Patents

Metodos para modular la funciòn de la vejiga

Info

Publication number
PA8720701A1
PA8720701A1 PA20078720701A PA8720701A PA8720701A1 PA 8720701 A1 PA8720701 A1 PA 8720701A1 PA 20078720701 A PA20078720701 A PA 20078720701A PA 8720701 A PA8720701 A PA 8720701A PA 8720701 A1 PA8720701 A1 PA 8720701A1
Authority
PA
Panama
Prior art keywords
bladder
function
methods
modulate
vesical
Prior art date
Application number
PA20078720701A
Other languages
English (en)
Inventor
Jacobson William
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38474526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8720701(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PA8720701A1 publication Critical patent/PA8720701A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

ESTA INVENCION PROVEE METODOS Y COMPOSICIONES FARMACEUTICAS PARA LA MODULACION DE LA FUNCION VESICAL Y EN PARTICULAR PARA EL MANTENIMIENTO DEL CONTROL DE L A VEJIGA O EL TRATAMIENTO DE INCONTINENCIA URINARIA.
PA20078720701A 2006-03-24 2007-03-23 Metodos para modular la funciòn de la vejiga PA8720701A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78545106P 2006-03-24 2006-03-24

Publications (1)

Publication Number Publication Date
PA8720701A1 true PA8720701A1 (es) 2008-11-19

Family

ID=38474526

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20078720701A PA8720701A1 (es) 2006-03-24 2007-03-23 Metodos para modular la funciòn de la vejiga

Country Status (15)

Country Link
US (2) US20070225274A1 (es)
EP (1) EP1998782A2 (es)
KR (1) KR20080107430A (es)
CN (1) CN101405005A (es)
AR (1) AR060324A1 (es)
AU (1) AU2007230891A1 (es)
BR (1) BRPI0709164A2 (es)
CA (1) CA2645099A1 (es)
CL (1) CL2007000774A1 (es)
IL (1) IL193841A0 (es)
MX (1) MX2008012105A (es)
PA (1) PA8720701A1 (es)
PE (1) PE20080125A1 (es)
TW (1) TW200806298A (es)
WO (1) WO2007112073A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
KR20080110759A (ko) * 2006-03-24 2008-12-19 와이어쓰 통증 치료
KR20080105104A (ko) * 2006-03-24 2008-12-03 와이어쓰 우울증 치료를 위한 신규한 치료학적 병용제
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
CN102482292B (zh) 2009-04-23 2017-07-18 Abbvie 公司 5‑ht受体的调节剂和其使用方法
US8518933B2 (en) * 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
US8546377B2 (en) * 2009-04-23 2013-10-01 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
ES2535490T3 (es) 2009-05-22 2015-05-12 Abbvie Inc. Preparación de moduladores de receptores 5-HT
CN104860951A (zh) * 2010-05-21 2015-08-26 Abbvie公司 5-ht受体的调节剂和其使用方法
AU2013314279B2 (en) 2012-09-14 2017-11-02 AbbVie Deutschland GmbH & Co. KG Tricyclic quinoline and quinoxaline derivatives
US20140080813A1 (en) 2012-09-14 2014-03-20 AbbVie Deutschland GmbH & Co. KG Tricyclic quinoline and quinoxaline derivatives
CN103204858A (zh) * 2013-03-20 2013-07-17 广州科瑞生物技术有限公司 基于酒石酸拆分合成工艺制备新型手性抗焦虑症药物
EP3116873B1 (en) 2014-03-14 2018-02-28 AbbVie Deutschland GmbH & Co. KG Hexahydrodiazepinoquinolines carrying a cyclic radical
WO2015136091A1 (en) 2014-03-14 2015-09-17 AbbVie Deutschland GmbH & Co. KG Hexahydrodiazepinoquinolines carrying a substituted alkyl radical
EP3380483A1 (en) 2015-11-25 2018-10-03 Abbvie Deutschland GmbH & Co. KG Hexahydropyrazinobenz- or -pyrido-oxazepines carrying an oxygen-containing substituent and use thereof in the treatment of 5-ht2c-dependent disorders
WO2018175449A1 (en) 2017-03-21 2018-09-27 AbbVie Deutschland GmbH & Co. KG Proline amide compounds and their azetidine analogues carrying a specifically substituted benzyl radical
KR20220041136A (ko) * 2019-07-30 2022-03-31 셀릭스 바이오 프라이빗 리미티드 항문 및 직장 질환 치료용 조성물 및 방법

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3417101A (en) * 1964-11-09 1968-12-17 American Home Prod Fused ring compounds
US3714149A (en) * 1969-11-03 1973-01-30 Upjohn Co Pyridobenzodiazepinones
US3914250A (en) * 1974-08-01 1975-10-21 American Home Prod 1,4-Diazepino{8 6,5,4-jk{9 carbazoles
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
NZ314105A (en) * 1996-02-02 1997-12-19 Sumitomo Pharma Guanidine derivative substituted with a substituted indole which is peri condensed with a heterocyclic ring
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
CO5210925A1 (es) * 1998-11-17 2002-10-30 Novartis Ag Derivados de diamino nitroguanidina tetrasustituidos
IL146582A0 (en) * 1999-05-21 2002-07-25 Biovitrum Ab Novel compounds, their use and preparation
JP3938689B2 (ja) * 2000-03-16 2007-06-27 エフ．ホフマン−ラ ロシュ アーゲー Ｉｐアンタゴニストとしてのカルボン酸誘導体
US6858604B2 (en) * 2000-11-03 2005-02-22 Wyeth Cyclohepta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AR031200A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados
AR031201A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp /1,4/diazepino/6,7,1-jk/carbazoles y derivados
US6777407B2 (en) * 2000-11-03 2004-08-17 Wyeth Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
DE60106641T2 (de) * 2000-11-03 2005-12-01 Wyeth Cyclopenta[b][1,4] diazepino[6,7,1-hi]indole als 5ht2c antagonisten
EP1343791A2 (en) * 2000-12-20 2003-09-17 Bristol-Myers Squibb Company Substituted tetracyclic pyridoindoles as serotonin agonists and antagonists
US6849619B2 (en) * 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
TWI312781B (en) * 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
JP5173190B2 (ja) * 2004-08-25 2013-03-27 武田薬品工業株式会社 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
PE20070549A1 (es) * 2005-10-17 2007-06-15 Wyeth Corp Tetrahidroquinolinas, su sintesis e intermediarios
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
CA2644618A1 (en) * 2006-03-24 2007-10-04 Wyeth Methods for treating cognitive and other disorders
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.

Also Published As

Publication number Publication date
US20070225274A1 (en) 2007-09-27
WO2007112073A3 (en) 2007-11-29
KR20080107430A (ko) 2008-12-10
BRPI0709164A2 (pt) 2011-06-28
WO2007112073A2 (en) 2007-10-04
PE20080125A1 (es) 2008-04-07
IL193841A0 (en) 2009-09-22
AR060324A1 (es) 2008-06-11
CN101405005A (zh) 2009-04-08
CA2645099A1 (en) 2007-10-04
AU2007230891A1 (en) 2007-10-04
MX2008012105A (es) 2008-10-03
CL2007000774A1 (es) 2008-03-07
US20090281091A1 (en) 2009-11-12
TW200806298A (en) 2008-02-01
EP1998782A2 (en) 2008-12-10

Similar Documents

Publication Publication Date Title
PA8720701A1 (es) Metodos para modular la funciòn de la vejiga
GT200600162A (es) Metodos para modular la funcion de la vejiga
CR11292A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
CL2007001788A1 (es) Composicion pesticida que incluye uno o mas nemacidas y uno o mas agentes de control biologico; procedimiento para tratar plantas y mejorar la salud de plantas de trasplante que comprende aplicar dicha composicion al material de propagacion.
ECSP099032A (es) Composiciones y métodos para la modulación del desarrollo vascular
AR079160A1 (es) Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina
EA200901653A1 (ru) ОПОСРЕДУЕМОЕ PHKi ИНГИБИРОВАНИЕ ЭКСПРЕССИИ АЛЬФА-EnaC
TNSN08400A1 (en) Organic compounds and their uses
CL2007003452A1 (es) Metodo para prevenir enfermedades de plantas causadas por microorganismos, fitopatogenos, que comprende aplicar la quinolina 3-(5-fluor-3,3-dimetil-3,4-dehidroisoquinolin-1-il)quinolina en tratamiento directo a las semillas.
CR20110626A (es) Composiciones farmacéuticas sólidas y procesos para su producción
ATE547130T1 (de) Biokompatibles implantat
BR112012004404A2 (pt) "lâmpada com movimento de líquido e método para controlar uma lâmpada com movimento de líquido"
EA201170821A1 (ru) Энзастаурин для лечения рака
TNSN08496A1 (en) Aminothiazoles and their uses
BRPI0604010A (pt) método para sanitizar uma superfìcie
AR060088A1 (es) Metodos para tratar trastornos cognitivos y otros afines
ECSP088761A (es) Nuevas combinaciones terapéuticas para el tratamiento o la prevención de trastornos psicóticos
BR112012015154A2 (pt) "combinação sinergética de protioconazol e metominostrobin."
WO2007137301A8 (en) Modulation of chrebp expression
NO20091691L (no) Pegylert PTH som PTH-reseptormodulatorer og anvendelse derav
DE502008001951D1 (de) Axomadol zur schmerzbehandlung bei arthrose
UY30769A1 (es) Uso de epotilonas en el tratamiento de la osteoporosis y enfermedades relacionadas
CL2008001553A1 (es) Uso de inhibidores de desacetilasa de histona para el tratamiento de la destrucción osea causada por enfermedades proliferativas, inflamatorias o por osteoporosis.
ES1058519Y (es) Malla para el tratamiento quirurgico de la incontinencia urinaria.
PH12014500538A1 (en) Methods and compositions for treating leukemia